Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statements of Profit or Loss 1 Interim Condensed Consolidated Statements of Comprehensive Income 2 Interim Condensed Consolidat

Quarterly Report of BioNTech SE for the Three And Nine Months Ended September 30, 2023

Our principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany. Our telephone number is +49 6131-9084-0. Our website address is www.biontech.com. The information contained on, or that can be accessed through, our website is not part of this document. Our agent for service solely for the purpose of notices and communications from the Securities and Exchange Commission in the United States is c o BioNTech US Inc., 40 Erie Street, Suite 110, Cambridge, Massachusetts 02139, +1 (617) 337-4701.

Unaudited Interim Condensed Consolidated Financial Statements

Operating and Financial Review and Prospects

Unaudited Interim Condensed Consolidated Financial Statements

Interim Condensed Consolidated Statements of Profit or Loss

The accompanying notes form an integral part of these interim consolidated financial statements.

Interim Condensed Consolidated Statements of Comprehensive Income

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Interim Condensed Consolidated Statements of Financial Position

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Interim Condensed Consolidated Statements of Changes in Stockholders' Equity

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Interim Condensed Consolidated Statements of Cash Flows

The accompanying notes form an integral part of these unaudited interim condensed consolidated financial statements.

Selected Explanatory Notes to the Unaudited Interim Condensed Consolidated Financial Statements

1Corporate Information

BioNTech SE is a limited company incorporated and domiciled in Germany. The registered office is located in Mainz, Germany (An der Goldgrube 12, 55131 Mainz). The accompanying unaudited interim condensed consolidated financial statements present the financial position and the results of operation of BioNTech SE and its subsidiaries and have been prepared on a going concern basis in accordance with the International Financial Reporting Standards, or IFRS as issued by the International Accounting Standards Board, or IASB. References to the "Company", "BioNTech", "Group", "we", "us" and "our" refer to BioNTech SE and its consolidated subsidiaries.

We are a global next-generation immunotherapy company pioneering novel medicines against cancer, infectious diseases and other serious diseases. Since our founding in 2008, we have focused on harnessing the power of the immune system to address human diseases with unmet medical need and major global health burden. Our fully integrated model combines decades of research in immunology, translational drug discovery and development, a technology agnostic innovation engine, GMP manufacturing, and commercial capabilities to rapidly discover, develop and commercialize our marketed products and other candidate vaccines and therapies. We have built a broad toolkit across multiple technology platforms, including a diverse range of potentially first-in-class therapeutic approaches. This includes mRNA vaccines and therapeutics, cell and gene therapies, targeted antibodies and small molecule immunomodulators.

Our unaudited interim condensed consolidated financial statements as of and for the three and nine months ended September 30, 2023 were authorized for issuance in accordance with a resolution of the audit committee on November 3, 2023.

2Basis of Preparation, Significant Accounting Policies and further Accounting Topics

Basis of Preparation and Principles of Consolidation

The accompanying unaudited interim condensed consolidated financial statements as of and for the three and nine months ended September 30, 2023 have been prepared in accordance with International Accounting Standard (IAS) 34 Interim Financial Reporting.

The unaudited interim condensed consolidated financial statements do not include all the information and disclosures required in the consolidated financial statements, and should be read in conjunction with our audited consolidated financial statements and accompanying notes included in our Annual Report on Form 20-F as of and for the year ended December 31, 2022.

We prepare and present our unaudited interim condensed consolidated financial statements in Euros and round numbers to millions of Euros. Accordingly, numerical figures shown as totals in some tables may not be exact arithmetic aggregations of the figures that preceded them and figures presented in the explanatory notes may not add up to the rounded arithmetic aggregations.

The unaudited interim condensed consolidated financial statements as of and for the three and nine months ended September 30, 2023 include BioNTech SE and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Significant Accounting Judgments, Estimates and Assumptions and Accounting Policies

The preparation of the unaudited interim condensed consolidated financial statements requires our management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the accompanying disclosures. This includes but is not limited to the judgment described as "Pfizer Agreement Characteristics" in the notes to our audited consolidated financial statements as of and for the year ended December 31, 2022. In order to determine our share of the collaboration partner's gross profits, we used certain information from the collaboration partner, including revenues from the sale of products and certain other sharable expense items some of which is based on preliminary data shared between the partners. Our management continually evaluates judgments and estimates, including those related to the contingencies, fair value measurement of derivatives, revenues and expenses. Management bases its judgments and estimates on parameters available when the unaudited interim condensed consolidated financial statements were prepared. Existing circumstances and assumptions about future developments,

however, may change due to market changes or circumstances arising that are beyond our control. Such changes are reflected in the assumptions when they occur.

Previously, we had assessed that inventory produced prior to successful regulatory approval did not meet the criteria for capitalization as an asset, and accordingly expensed the costs of pre-launch inventory as research and development costs. Based on the experience of the past years and the developments since our COVID-19 vaccine was first authorized or approved for emergency or temporary use, our assessment regarding the potential to produce economic benefits changed. Beginning with the second quarter of 2023, pre-launch products from the Comirnaty product family with their potential for economic benefit fulfill the recognition criteria for an asset under the IFRS Conceptual Framework. At each reporting date, the respective inventory is measured at the lower of cost and net realizable value. Until regulatory approval is obtained, we consider the net realizable value to be zero, as this is the probable amount expected to be realized from its sale until approval is obtained. The write-down is recognized in the statements of profit or loss as research and development expenses. Once regulatory approval for a product candidate is obtained, including for approved Comirnaty vaccines, the relevant write-down is reversed to a maximum of the original cost. Subsequently, inventory will be recognized as cost of sales. This reassessment made during the three month ended September 30, 2023, has been treated as a change in estimate and the impacts on current period inventories, cost of sales and research and development expenses is described in Note 4.1.

The accounting policies adopted in the preparation of the unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of our audited consolidated financial statements as of and for the year ended December 31, 2022, except for income taxes, which are accounted for using the expected annual tax rate in our unaudited interim condensed consolidated financial statements (see Note 6). Certain policies are described further below due to the activities and transactions during the three and nine months ended September 30, 2023.

Standards Applied for the First Time

The IFRS standards applied for the first time as of January 1, 2023, as disclosed in the notes to the audited consolidated financial statements as of and for the year ended December 31, 2022, had no impact on our unaudited interim condensed consolidated financial statements as of and for the three and nine months ended September 30, 2023.

3Revenues from Contracts with Customers

Disaggregated information on revenues

Set out below is the disaggregation of our revenues from contracts with customers

(1) Represents sales to our collaboration partners of products manufactured by us and reflects manufacturing costs and variances to the extent identified.

During the three and nine months ended September 30, 2023, and 2022, commercial revenues were recognized from the supply and sales of our COVID-19 vaccine worldwide. During the three and nine months ended September 30, 2023 our commercial revenues decreased corresponding with a lower COVID-19 vaccine market demand. Write-downs by our collaboration partner Pfizer Inc, or Pfizer, significantly reduced our gross profit share and hence negatively influenced our revenues for three months ended September 30, 2023.We are the marketing authorization holder in the United States, the European Union, the United Kingdom, Canada and other countries, and holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer Inc., or Pfizer) and other countries. Pfizer has marketing and distribution rights worldwide with the exception of China, Germany and Turkey. Shanghai Fosun

Pharmaceutical (Group) Co., Ltd, or Fosun Pharma, has marketing and distribution rights in China, Hong Kong special administrative region, or SAR, Macau SAR and the region of Taiwan. The allocation of marketing and distribution rights defines territories in which the collaboration partners act as a principal.

Sales to Collaboration Partners

Sales to collaboration partners represent sales of products manufactured by us to collaboration partners. Whenever responsibilities in the manufacturing and supply process of the COVID-19 vaccine shift and the COVID-19 vaccine is transferred, the vaccine is sold from one partner to the other. Under the collaboration with Pfizer, from time to time, those sales are significantly influenced by amounts due to write-downs of inventories as well as costs related to production capacities derived from contracts with Contract Manufacturing Organizations (CMOs) that became redundant. Those costs represent accrued manufacturing variances and are charged to our partner once finally materialized. These manufacturing variances are reflected as transfer price adjustment once identified. The regular reassessment of these manufacturing variances might result in minor reversals of the respective prior period revenues. Sales to collaboration partners during the three and nine months ended September 30, 2023, amounted to (17.7) million and 128.9 million, respectively. During the three and nine months ended September 30, 2022 the sales to collaboration partners amounted to 259.4 million and 1,470.9 million, respectively. During the three and nine months ended September 30, 2023 those sales included (72.5) million and 44.4 million, respectively, related to the aforementioned manufacturing variances ( 161.6 million and 956.8 million with respect to sales during the three and nine months ended September 30, 2022).

Direct Product Sales to Customers

By supplying our territories during the three and nine months ended September 30, 2023, we recognized 195.7 million and 260.9 million of revenues, respectively, from direct COVID-19 vaccine sales in Germany. During the three and nine months ended September 30, 2022, recognized revenues derived from those sales amounted to 564.5 million and 2,284.6 million, respectively. The share of gross profit that we owe our collaboration partner Pfizer based on our sales is recognized as cost of sales. Alongside with the amended COVID-19 Vaccine Purchase Agreement with the European Commission, an amount of 372.3 million remained as contract liability in our unaudited interim condensed consolidated statements of financial position. The amount will be recognized over the term of the agreement.

Share of Collaboration Partners' Gross Profit

Based on COVID-19 vaccine sales in the collaboration partners' territories, we are eligible to receive a share of their gross profit, which represents a seasonally-affected net figure and is recognized as collaboration revenue during the commercial phase. When determining the gross profit, manufacturing cost variances either reflected as transfer price adjustment as described above, or resulting from costs expected to be incurred by the partner were considered. During the three and nine months ended September 30, 2023, 707.0 million and 1,916.9 million, respectively, in gross profit share was recognized as revenues. During the three and nine months ended September 30, 2022, 2,554.2 million and 9,128.4 million, respectively, in gross profit share was recognized as revenues.

Revenues from contracts with customers were recognized as follows

(1) Represents sales based on the share of the collaboration partners' gross profit.

4Income and Expenses

The cost of sales recognized during the three and nine months ended September 30, 2023, and 2022 are shown in the following table

Based on the regulatory approval obtained during the three and nine months ended September 30, 2023, we reversed the initial write-down of prelaunch inventory recorded in research and development expenses to a maximum of the original cost of 46.9 million. Thereof 27.3 million resulted in cost of sales of the period as the respective inventory has been either sold or written-down. The remainder is presented in inventories as of September 30, 2023 and amounted to 19.6 million. With respect to the prior year period the amount was nil.

4.2Research and Development Expenses

The research and development expenses recognized during the three and nine months ended September 30, 2023, and 2022 are shown in the following table

4.3General and Administrative Expenses

The general and administrative expenses recognized during the three and nine months ended September 30, 2023, and 2022 are shown in the following table

4.4Other Operating Expenses

The other operating expenses recognized during the three and nine months ended September 30, 2023, and 2022 are shown in the following table

The foreign exchange differences included in operating expenses primarily arose from valuing our U.S. dollar denominated trade receivables which mainly resulted from our COVID-19 collaboration with Pfizer, compensated by the foreign exchange rate effects of our U.S. dollar denominated trade payables as well as our U.S. dollar denominated other financial liabilities which mainly resulted from obligations incurred from our license agreements.

The loss on derivative instruments at fair value through profit or loss in the prior year comparable period related to foreign exchange forward contracts that were entered into to manage some of our transaction exposures but were not designated as hedging instruments under IFRS (see Note 8).

4.5Other Operating Income

The other operating income recognized during the three and nine months ended September 30, 2023, and 2022 is shown in the following table

The gain on derivative instruments at fair value through profit or loss related to foreign exchange forward contracts that did not qualify for hedge accounting (see Note 8).

The foreign exchange differences in the prior year comparable period included in operating income primarily arose from valuing our U.S. dollar denominated trade receivables which mainly relate to our COVID-19 collaboration with Pfizer, U.S. dollar denominated trade payables as well as our U.S. dollar denominated other financial liabilities which mainly relate to obligations incurred from our license agreements.

The finance income recognized during the three and nine months ended September 30, 2023, and 2022 is shown in the following table

During the three and nine months ended September 30, 2023, interest income was mainly derived from our debt security investments as well as bank deposits and the fair value adjustments were derived from remeasuring our money market funds.

During the three and nine months ended September 30, 2022, foreign exchange differences were mainly derived from our foreign exchange bank deposits and cash accounts, respectively. In addition, during the nine months ended September 30, 2022, the fair value adjustments derived from remeasuring the derivative embedded in our convertible note significantly affected our finance result.

In the interim condensed consolidated statements of cash flows, the change in cash and cash equivalents resulting from exchange rate differences amounted to 5.8 million and 5.6 million during the three and nine months ended September 30, 2023, respectively.

In the interim condensed consolidated statements of cash flows, the change in cash and cash equivalents resulting from exchange rate differences amounted to 46.7 million and 211.7 million during the three and nine months ended September 30, 2022, respectively.

5Business Combination

Acquisition of InstaDeep Ltd.

In July 2023, we acquired InstaDeep Ltd., London, or InstaDeep, a leading global technology company in the field of artificial intelligence, or AI, and machine learning, by purchasing 100% of the remaining shares in InstaDeep not already owned by us. The acquisition is intended to create a fully integrated, enterprise-wide capability that leverages AI and machine learning technologies across our therapeutic platforms and operations. InstaDeep also continues to provide its services to clients around the world in diverse industries, including in the Technology, Transport Logistics, Industrial and Financial Services sectors.

The completion of the acquisition in July 2023 was accounted for as a business combination using the acquisition method of accounting. We performed an allocation of the total consideration and the underlying assets acquired (including certain identified intangible assets as InstaDeep's DeepChain technology and customer relationships) and liabilities assumed based on their fair values using the information available as of the acquisition date. The total consideration and the fair values in accordance with IFRS 3 of the identified net assets acquired of InstaDeep as of July 31, 2023 are as follows

The intangible assets acquired comprise DeepChain technology and customer relationships. Their fair values were determined based on the multi-period excess earnings method (MEEM) and amount to 176.0 million and 7.8 million respectively.

The fair value of the shares transferred is determined based on the number of shares transferred and our closing stock price as of July 31, 2023.

The acquisition of InstaDeep is a step-acquisition according to IFRS 3.41-3.42A since we already held 5.3% prior to the acquisition. In prior reporting periods, we recognized changes in the value of this equity interest in other comprehensive income. The amount of the remeasurement to fair value that was recognized in other comprehensive income is recognized on the same basis as would be required if we disposed directly of the previously held equity interest. Based on the total consideration for the acquired shares (94.7%) the value of the already held shares is 27.9 million, which results in a loss of 2.2 million shown in other comprehensive income in the three and nine months ended September 30, 2023.

At the acquisition date, the contingent consideration was recognized with its fair value of 31.8 million based on cash flow projections in connection with performance-based future milestone payments to eligible shareholders after a three-year earn-out period. The lower end of the bandwidth of possible outcomes of the contingent consideration is zero the upper limit is 124.6 million. In addition, 12.5 million of potential earn-out payments are considered remuneration and will be recognized as personnel expense over a three-year period in which services are to be provided.

The goodwill mainly comprises the value of expected synergies from including AI and machine learning technologies across our therapeutic platforms and operations and intangible assets that are not recognized separately, e.g., the acquired skilled workforce and its know-how. Therefore, the goodwill is almost fully allocated to the CGU immunotherapies and a minor part to a CGU comprising the external InstaDeep business. The goodwill is not tax deductible.

Deferred tax liabilities relating to temporary differences of the assets acquired in the business combination were recognized at an amount of 45.8 million. To the extent of those deferred tax liabilities assumed, deferred tax assets relating to temporary differences and tax loss carryforwards which existed as of the acquisition date were recognized. To the extent the conditions to offset were fulfilled, the deferred tax assets and liabilities were offset.

For the nine months ended September 30, 2023 and 2022, income taxes were calculated based on the best estimate of the weighted average annual income tax rates expected for the full financial years (estimated annual effective income tax rates) on ordinary income before tax adjusted by the tax effect of any discrete items. The income tax asset represents the portion of prepayments for corporate income taxes and trade taxes in Germany that have been paid for the full financial year 2023 but not yet offset by income tax expenses calculated for the nine months ended September 30, 2023. For the nine months ended September 30, 2023 and 2022, our effective income tax rates were approximately 9.7% and 26.8%, respectively. The decrease of the effective income tax rate was mainly driven by the transaction within the BioNTech Group described below. During the nine months ended September 30, 2023 and 2022, current income taxes were mainly recognized with respect to the German tax group. Deferred tax effects were recognized with respect to identified discrete items as well as share-based payments programs during the nine months ended September 30, 2023 and 2022.

A reorganization of the intellectual property rights within the group has become effective June 30, 2023 and July 1, 2023 which led to deferred tax effects in Germany, the US and Austria. As a result BioNTech SE recognized deferred tax assets and deferred tax income at the time of the transaction. In addition this transaction led to a revaluation of previously unrecognized U.S. federal and state deferred tax assets, including unused tax losses and unused tax credits. As of December 31, 2022, there were unrecognized U.S. federal and state deferred tax assets of 128.9 million. As of September 30, 2023, it is considered highly probable that taxable profits for the U.S. tax group will be available against which the deferred tax assets can be utilized in the near future fulfilling the requirements set out by IAS 12. Therefore we no longer continue to maintain the full non-recognition of deferred tax assets of our U.S. tax group as there will be future taxable profits available against which the unused tax losses and temporary differences can be utilized. As of September 30, 2023, we maintain the non-recognition of deferred tax assets for unused U.S. federal and state tax losses at an amount of 20.1 million and 1.6 million, respectively, as there is not sufficient probability in terms of IAS 12 that there will be future taxable income available against which these unused tax losses can be utilized.

The income taxes recognized during the three and nine months ended September 30, 2023, and 2022 are shown in the following table

The increase in intangible assets by 507.0 million from December 31, 2022 to September 30, 2023 was mainly related to the acquisition of InstaDeep (see Note 5) and licenses fulfilling the definition of identifiable assets in the amount of 328.9 million acquired in connection with the license and collaboration agreements entered into between us and Duality Biologics (Suzhou) Co. Ltd., Shanghai, China, in March 2023 and August 2023 as well as the license and collaboration agreement entered into between us and OncoC4 Inc., Rockville (Maryland), United States, in April 2023.

8Financial Assets and Financial Liabilities

Set out below is an overview of financial assets, other than cash and cash equivalents, held as of September 30, 2023 and December 31, 2022.